1. INVESTOR FACT SHEET
Period ended June 30, 2012
Corporate profile Symbol
AxoGen, Inc. is a leading regenerative medicine company focused on the commercialization AXGN
of its portfolio of proprietary products and technologies for peripheral nerve reconstruction
Exchange
and regeneration.
OTCBB
Headquarters: Alachua, FL Price at 08.15.12
Number of employees: 46 $3.25
Products and Services: Peripheral Nerve Reconstruction
52-Week High
Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and $4.00
their damage can result in the loss of function and feeling. In order to improve surgical reconstruction 52-Week Low
and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent- $1.10
pending technologies, which are used in its portfolio of products. This portfolio includes Avance®
Nerve Graft, the only commercially available allograft nerve for bridging peripheral nerve discontinuities Market Capitalization
(a gap created when the nerve is severed) of up to 70mm in length. $36 Million
AxoGen’s portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close 2Q12 Revenues
approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a $2.0 Million
coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen is bringing
the science of nerve repair to life with thousands of surgical implants of AxoGen products performed Cash
in hospitals and surgery centers across the United States, including military hospitals serving U.S. $4.6 Million
service men and women.
Total
Debt Outstanding
$5.0 Million
Strong performance
dollars in millions, except where noted
Revenues Gross Profit Second quarter
2012 highlights
$4.8
$3.7 Record second quarter
$3.3 revenues
Record revenues of $2.01 million, a
$3.0 64% increase from second quarter
$2.7
2011
$2.0 Achieved record profit margins
Gross profit for second quarter
$1.5 $1.6
2012 increased 89% to a record
$1.2 $1.5 million
$0.8 Gross profit margins improved to
75% compared to 65% for the
same period in 2011
2Q11 2Q12 2010 2011 YTD 2012 2Q11 2Q12 2010 2011* YTD 2012
*Excludes one-time write-off of inventory
Continued >

2. Financial summary
dollars in thousands
2Q 2012 1Q 2012 2Q 2011 2011(1)
Income Statement:
Net Revenues $2,012 $1,653 $1,225 $4,849
Gross Profit $1,510 $1,214 $801 $2,422
Gross Margin 75% 73% 65% 50%
Net Income (Loss) (2) ($1,766) ($2,109) ($1,678) ($9,220)
Balance Sheet:
Cash & Cash Equivalents $4,638 $5,642 $2,230 $8,191
1. Gross Profit excludes one-time write-off of inventory
2. Excludes non-recurring income tax benefit of $736,000 for 2Q 2012.
Business summary Investment highlights
• The US market opportunity
AxoGen is a regenerative medicine company with a proprietary product portfolio for exceeds $1 billion
peripheral nerve reconstruction and regeneration in a wide range of nerve gap sizes.
• First mover in peripheral nerve
mm
gap reconstruction
• Processed nerve
70
allograft for bridging • Only complete peripheral nerve
65 severed peripheral product portfolio
60 nerves
• Highly scalable infrastructure
55
50 • Poised for rapid growth
45
40
35 • Wraps and protects injured
nerves
30 2012 objectives
25 • Reinforces coaptation
20
• Increase investment in sales and
15
marketing
10
• Bridges gaps up to 5mm • Execute on commercialization
5 strategy
• Coaptation aid
0
• Expand to new markets, while
penetrating existing markets
The January, 2012 edition of Microsurgery contains an article summarizing the RANGER study results • Educate the market about
to date, reporting over 87% meaningful recovery in sensory, motor and mixed nerve injuries treated products’ value proposition
with the Avance® Nerve Graft (Published Microsurgery DOI: 10.1002/micr.20975.)
“ It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery 21
depends on the type of injury, length of nerve discontinuity, the patient’s age and the type of nerve.
Our study findings show that with processed nerve allograft, patients can have meaningful recovery
regardless of these factors.
Based on our findings, the information I use to counsel my patients prior to surgery will change — this
”
is a paradigm shift.
Darrell Brooks, M.D., plastic surgeon,
The Buncke Clinic
Company leadership: Company contact: Investor contact:
Karen Zaderej – Chief Executive Officer Greg Freitag
Greg Freitag – Chief Financial Officer Chief Financial Officer
Jill Schiaparelli – SVP Business Strategy & Marketing AxoGen, Inc. 1230 Peachtree Street
13859 Progress Blvd., Suite 100 19th Floor
John Engels – Vice President
Alachua, FL 32615 Atlanta, GA 30309
Mark Friedman, Ph.D. – VP of Regulatory Affairs
P 972.308.6830 P 404.942.3369
Brad Hedger – VP of Sales
axogeninc.com cockrellgroup.com